Summary of Key Points Core Viewpoint - A total of 21 companies listed on the Beijing Stock Exchange have announced cash dividend distribution plans for the first half of the year, with all of them involving cash payouts [1]. Group 1: Dividend Distribution Details - Jinbo Biological announced the most generous cash dividend plan, proposing a distribution of 10 yuan per 10 shares, amounting to a total cash payout of 115 million yuan [1]. - Other notable companies include Tiangong Co. and Guangxin Technology, with cash payouts of 65.56 million yuan and 59.9997 million yuan, respectively [1]. - Three companies have a cash payout exceeding 5 yuan per 10 shares: Jinbo Biological, Youli Intelligent, and Guangxin Technology, with payouts of 10 yuan, 10 yuan, and 6.56 yuan respectively [1]. Group 2: Dividend Payout Ratios - Companies with the highest cash payout ratios relative to net profit include Xuchang Intelligent, Lude Medical, and Liandi Information, with payout ratios of 290.92%, 175.68%, and 117.02% respectively [1]. - The cash payout amounts and their respective ratios indicate a trend of high returns to shareholders among these companies [1]. Group 3: Stock Performance Post-Dividend Announcement - The stock performance following the announcement of dividend plans shows varied reactions, with some companies experiencing declines while others saw increases [1]. - For instance, Jinbo Biological's stock dropped by 5.33% the day after the announcement, while Youli Intelligent's stock increased by 0.80% [1].

Group 1 - The medical beauty sector increased by 0.6% on August 28, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] - The closing prices and performance of key stocks in the medical beauty sector include: - Huaxi Biological: 57.78, up 1.60%, with a trading volume of 82,100 shares and a turnover of 471 million yuan - Aimeike: 190.36, up 0.17%, with a trading volume of 49,700 shares and a turnover of 940.1 million yuan - Jinbo Biological: 299.27, down 1.81%, with a trading volume of 9,644 shares and a turnover of 289 million yuan - *ST Meigu: 3.21, down 3.60%, with a trading volume of 195,800 shares and a turnover of 62.64 million yuan [1] Group 2 - The medical beauty sector experienced a net outflow of 122 million yuan from main funds, while retail funds saw a net inflow of 66.68 million yuan [1] - The fund flow for key stocks shows: - *ST Meigu: net outflow of 5.87 million yuan, down 9.37% - Huaxi Biological: net outflow of 27.85 million yuan, down 5.92% - Aimeike: net outflow of 88.21 million yuan, down 9.39% [2]

Core Insights - As of August 27, the total margin financing and securities lending balance on the Beijing Stock Exchange reached 7.473 billion yuan, an increase of 93.49 million yuan from the previous trading day, marking three consecutive days of increase [1] - The top three stocks by margin financing balance are Jinbo Biological, Shuguang Digital Innovation, and Airun Software, with balances of 332 million yuan, 229 million yuan, and 179 million yuan respectively [1] - A total of 152 stocks had net margin purchases on August 27, with 14 stocks having net purchases exceeding 5 million yuan, led by Shuguang Digital Innovation with a net purchase of 16.27 million yuan [1][2] Margin Financing Overview - The margin financing balance increased by 93.37 million yuan to 7.472 billion yuan, while the securities lending balance rose by 125,400 yuan to 59,390 yuan [1] - The average margin financing balance as a percentage of market capitalization for the stocks with the highest balances is 1.33%, with Minshida, Wanyuantong, and Dezhong Automobile leading at 4.57%, 4.02%, and 3.79% respectively [1][2] Industry Performance - The industries with the highest concentration of stocks with net margin purchases over 5 million yuan include power equipment, automotive, and computer sectors, with 4, 3, and 3 stocks respectively [2] - On average, stocks with net margin purchases over 5 million yuan saw a decline of 2.69%, with the top gainers being Wantong Hydraulic, Shuguang Digital Innovation, and Suzhou Axle, which increased by 4.42%, 0.87%, and 0.36% respectively [2] Stock Activity - The weighted average turnover rate for stocks with net margin purchases over 5 million yuan was 4.27%, with the highest turnover rates recorded for Nengzhiguang, Hengtou Kaiyuan, and Wantong Hydraulic at 35.12%, 12.94%, and 12.65% respectively [2] - The average daily turnover rate for stocks on the Beijing Stock Exchange was 5.45% on August 27 [2] Notable Stocks - Stocks with the largest increases in margin financing on August 27 include Shuguang Digital Innovation (increase of 16.27 million yuan), Juxing Technology (increase of 8.28 million yuan), and Hengtou Kaiyuan (increase of 7.93 million yuan) [3][4] - Stocks with significant net margin sales included Dingzhi Technology, Wuxin Tunnel Equipment, and Kaitex, with net sales of 11.33 million yuan, 8.29 million yuan, and 5.35 million yuan respectively [1]

Core Insights - The "specialized and innovative" small giants are accelerating, with hidden champions in niche industries increasing their market share [1] - As of August 27, 2025, 192 out of 273 listed companies on the North Exchange have released their semi-annual reports, with a profitability rate of approximately 87.5% [1] - The majority of profitable companies are concentrated in the machinery equipment (24%), automotive (11%), electric power equipment (10%), and basic chemicals (10%) sectors [1] Revenue Performance - Nine companies on the North Exchange achieved revenue exceeding 1 billion yuan in the first half of 2025, with 150 companies surpassing 100 million yuan [3] - The top three companies by revenue are: - Innoway: 3.55 billion yuan - Tongli Co., Ltd.: 3.17 billion yuan - Yingtai Biotechnology: 2.97 billion yuan [4] Profitability - Three companies reported a net profit exceeding 100 million yuan, while 22 companies had a net profit over 50 million yuan [5] - Jinbo Biological, a leading company in the medical beauty and functional skincare sector, reported a net profit of 392 million yuan, a year-on-year increase of 26.65% [6][7] Growth Rates - Among the 22 companies that doubled their profits, Shibi Bai reported a staggering net profit growth of nearly 60 times, achieving a net profit of approximately 29.23 million yuan [9] - The company attributed its success to increased sales driven by government subsidies and improved internal management, leading to enhanced product quality and profit margins [9] Industry Trends - The machinery equipment sector has a high representation among the profitable companies, with Tongli Co., Ltd. being one of the notable firms with a market capitalization of approximately 10.31 billion yuan [9] - Tongli Co., Ltd. is actively advancing in the fields of new energy and autonomous driving, having delivered seven electric non-road dump trucks for a project in Mongolia [10]

中信证券股份有限公司 关于山西锦波生物医药股份有限公司 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》 等有关法律法规、规范性文件等的规定，中信证券股份有限公司（以下简称"中 信证券"或"保荐机构"）山西锦波生物医药股份有限公司（以下简称"锦波生 物""上市公司""公司"）的保荐机构，负责锦波生物的持续督导工作，并出具 2025 年半年度持续督导跟踪报告。 | 序号 | 工作要求 | 完成或督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导业务管理制度，制 | 中信证券已建立健全并有效执 | | | 定持续督导工作计划和实施方案，就持续督导工 | 行持续督导工作制度，并已根据 | | | 作的主要内容、重点、实施方式、步骤等做出完 | 上市公司的具体情况制定了相 | | | 整、有效的安排。 | 应的持续督导工作计划和安排。 | | | | 本持续督导期间，保荐机构查阅 | | | | 了上市公司《公司章程》《承诺 | | | | 管理制度》《内部审计制度》《关 | | | 督导上市公司建立健全并有效执行公司治理制 | 联交易管理制度》等公司内部制 ...

Market Overview - The medical beauty sector experienced a decline of 3.11% on August 27, with Aimeike leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Aimeike (300896) closed at 190.03, down 3.88%, with a trading volume of 62,200 shares and a transaction value of 1.207 billion yuan [1] - Huaxi Biological (688363) closed at 56.87, down 2.25%, with a trading volume of 99,400 shares and a transaction value of 580 million yuan [1] - Jinbo Biological (832982) closed at 304.80, down 3.24%, with a trading volume of 10,300 shares and a transaction value of 319 million yuan [1] - ST Meigu (000615) remained unchanged at 3.33, with a trading volume of 142,300 shares and a transaction value of 47.7013 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 199 million yuan from main funds, while retail investors contributed a net inflow of 153 million yuan [1] - Aimeike experienced a net outflow of 143 million yuan from main funds, with retail investors contributing a net inflow of 98.8281 million yuan [2] - Huaxi Biological had a net outflow of 57.973 million yuan from main funds, but a net inflow of 53.4443 million yuan from retail investors [2]

证券代码：832982 证券简称：锦波生物 公告编号：2025-142 山西锦波生物医药股份有限公司 股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 1,559,969 股，占公司总股本 1.356%，可交 易时间为 2025 年 8 月 29 日。 注：如公司近期办理过新增股份登记的，公司总股本以新增股份登记后的总股本为准。 四、其它情况 本次解除限售的股东如属于《北京证券交易所股票上市规则》《北京证券交 易所上市公司持续监管指引第 8 号——股份减持》等规定的减持预披露主体，若 后续减持股份，将在减持前及时履行信息披露义务。 二、本次股票解除限售的明细情况及原因 单位：股 | 序号 | 股东姓 名或名 | 是否为 控股股 东、实际 | 董事、监事、 | 本次解 | 本次解除限 | 本次解除 限售股数 | 尚未解除 限售的股 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has achieved revenue and profit growth in the first half of 2025, driven by the sales of its A-type recombinant human collagen products and the approval of new gel products [5][6] - The company is expanding its sales channels, with its "Wei Yi Mei" brand products covering over 4,000 medical institutions [5][6] - The company plans to raise 2 billion RMB through a private placement to enhance its research and development capabilities and expand its product offerings [5][7] Summary by Sections Market Performance - The closing price as of August 25, 2025, is 316.46 RMB, with a market capitalization of 36,413.58 million RMB [3] Financial Performance - Revenue has grown from 161 million RMB in 2020 to 1.443 billion RMB in 2024, with a compound annual growth rate (CAGR) of 72.9% [6][12] - The net profit attributable to the parent company reached 732 million RMB in 2024, with a CAGR of 118.8% from 2020 to 2024 [6][12] - In the first half of 2025, the company reported revenue of 859 million RMB, a year-on-year increase of 42.43%, and a net profit of 392 million RMB, up 26.65% year-on-year [6][12] Product Development and Market Strategy - The company has received regulatory approval for its "Injection of Recombinant Type III Humanized Collagen Gel," which is expected to enhance its product lineup [5][19] - The company is focusing on expanding its international presence, having obtained medical device registration in Thailand and certifications in the USA and Saudi Arabia for its functional skincare products [5][19] - The company is collaborating with strategic investor Yangsheng Tang to enhance its R&D and commercialization efforts [7][24] Future Outlook - The company forecasts net profits of 1.018 billion RMB, 1.410 billion RMB, and 1.833 billion RMB for 2025, 2026, and 2027, respectively, with corresponding price-to-earnings ratios of 36, 26, and 20 times [7][8] - The company aims to leverage its technological advancements in collagen products to capture a larger market share in the medical aesthetics and functional skincare sectors [5][9]

Group 1 - The medical beauty sector increased by 0.48% on August 25, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - The trading volume and turnover for key stocks in the medical beauty sector were reported, with Aimeike and Huaxi Biological showing notable figures [1] Group 2 - The net inflow of main funds in the medical beauty sector was 11.25 million yuan, while retail investors saw a net inflow of 37.19 million yuan [1] - Aimeike had a main fund net inflow of 5.73 million yuan, but a significant outflow from speculative funds of 36.09 million yuan [2] - Huaxi Biological experienced a main fund net inflow of 4.79 million yuan, with a minor outflow from speculative funds [2]

Market Trends - The online sales proportion of small home appliances in China increased from 68% in 2020 to 79% in 2024, while offline retail sales of kitchen appliances are expected to decline by 9.1% year-on-year in 2024[2] - The small home appliance market in China is projected to reach a scale of 539.2 billion yuan by 2027[20] - In the first five months of 2025, the sales revenue of small home appliances reached 61.5 billion yuan, with a growth rate of 16.1%[24] Policy Impact - The "old for new" policy in the appliance sector has expanded to include 12 categories, stimulating market recovery and showing significant consumer potential[24] - In 2025, the total sales of the home appliance market reached 402.2 billion yuan, reflecting a year-on-year growth of 12.7%[24] Stock Performance - The median stock price change for consumer service stocks on the Beijing Stock Exchange was +4.34% from August 18 to August 22, 2025, with 95% of companies experiencing an increase[42] - The total market capitalization of consumer service companies rose from 118.94 billion yuan to 126.47 billion yuan during the same period[45] Valuation Metrics - The median price-to-earnings (P/E) ratio for consumer service companies increased from 50.4X to 52.3X[44] - The median P/E ratio for the broader consumer sector rose by 10.32% to 79.7X[51]